
    
      This study is a double-blind, three-arm, parallel group, single-dose study. A total of 141
      subjects will be enrolled; 47 subjects in each of the 3 arms of the clinical study. In each
      arm, all subjects will receive a single dose (5 mg/kg) of either CT-P16, EU-approved Avastin,
      or US-licensed Avastin by intravenous (IV) infusion for 90 min (Â±5 min) on Day 1 followed by
      15 weeks during which the PK, safety, and immunogenicity measurements will be made. The
      randomization will be stratified by body weight and site.
    
  